How has mass drug administration with dihydroartemisinin-piperaquine impacted molecular markers of drug resistance? A systematic review

Moss, Sophie; Mańko, Emilia; Krishna, Sanjeev; Campino, Susana; Clark, Taane G.; Last, Anna

doi:10.1186/s12936-022-04181-y

Cited by 4 publications

(5 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Digestive vacuole pfcrt, pfmdr1, pvmdr1 [17,18,20,24,88,91] Amodiaquine pfcrt, pfmdr1 [17,18,20] Piperaquine pfcrt, pfmdr1, plm2 and plm3 amplification [18,20,21,26] Pyronaridine pfcrt [20] Naphthoquine Unknown [20] 8-Aminoquinoline Primaquine Unknown Unknown Unknown [18,20] Tafenoquine Unknown Naphthoquinone Atovaquone Inhibition of mitochondrial electron transport (cytochrome b1 complex)…”

Section: -Aminoquinoline Chloroquine Interferes Hemozoin Formationmentioning

confidence: 99%

“…25 Resistance to piperaquine is correlated with gene plasmepsins pfpm2 and pfpm3. 21,26 It was proposed that overproduction of these plasmepsins might interfere with piperaquine's inhibition of heme detoxification processes in the digestive vacuole. 21,26 However, it could not be confirmed whether plasmepsin is directly involved in mediating piperaquine resistance or was a compensatory mechanism for the fitness disadvantage of the actual resistance determinant.…”

Section: -Aminoquinoline (Chloroquine and Piperaquine)mentioning

confidence: 99%

“…21,26 It was proposed that overproduction of these plasmepsins might interfere with piperaquine's inhibition of heme detoxification processes in the digestive vacuole. 21,26 However, it could not be confirmed whether plasmepsin is directly involved in mediating piperaquine resistance or was a compensatory mechanism for the fitness disadvantage of the actual resistance determinant. 21 Plasmodium falciparum piperaquine resistance is influenced by multiple factors, mainly the polymorphisms of pfcrt and pfmdr1.…”

Section: -Aminoquinoline (Chloroquine and Piperaquine)mentioning

confidence: 99%

See 2 more Smart Citations

Antimalarial Drug Resistance: A Brief History of Its Spread in Indonesia

Fitri,

Pawestri,

Winaris

et al. 2023

DDDT

View full text Add to dashboard Cite

Malaria remains to be a national and global challenge and priority, as stated in the strategic plan of the Indonesian Ministry of Health and Sustainable Development Goals. In Indonesia, it is targeted that malaria elimination can be achieved by 2030. Unfortunately, the development and spread of antimalarial resistance inflicts a significant risk to the national malaria control programs which can lead to increased malaria morbidity and mortality. In Indonesia, resistance to widely used antimalarial drugs has been reported in two human species, Plasmodium falciparum and Plasmodium vivax. With the exception of artemisinin, resistance has surfaced towards all classes of antimalarial drugs. Initially, chloroquine, sulfadoxine-pyrimethamine, and primaquine were the most widely used antimalarial drugs. Regrettably, improper use has supported the robust spread of their resistance. Chloroquine resistance was first reported in 1974, while sulfadoxine-pyrimethamine emerged in 1979. Twenty years later, most provinces had declared treatment failures of both drugs. Molecular epidemiology suggested that variations in pfmdr1 and pfcrt genes were associated with chloroquine resistance, while dhfr and dhps genes were correlated with sulfadoxine-pyrimethamine resistance. Additionally, G453W, V454C and E455K of pfk13 genes appeared to be early warning sign to artemisinin resistance. Here, we reported mechanisms of antimalarial drugs and their development of resistance. This insight could provide awareness toward designing future treatment guidelines and control programs in Indonesia.

show abstract

Section: -Aminoquinoline Chloroquine Interferes Hemozoin Formationmentioning

confidence: 99%

Section: -Aminoquinoline (Chloroquine and Piperaquine)mentioning

confidence: 99%

Section: -Aminoquinoline (Chloroquine and Piperaquine)mentioning

confidence: 99%

See 1 more Smart Citation

Antimalarial Drug Resistance: A Brief History of Its Spread in Indonesia

Fitri,

Pawestri,

Winaris

et al. 2023

DDDT

View full text Add to dashboard Cite

show abstract

“…DP MDA in The Gambia also resulted in a significant reduction in infection incidence; however, these gains were short-lived in higher transmission areas 16. There is currently little evidence of DP resistance in Africa,17 although surveillance data following MDA are lacking 18…”

Section: Introductionmentioning

confidence: 99%

“… 16 There is currently little evidence of DP resistance in Africa, 17 although surveillance data following MDA are lacking. 18 …”

Section: Introductionmentioning

confidence: 99%

Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial

et al. 2023

View full text Add to dashboard Cite

IntroductionAs malaria declines, innovative tools are required to further reduce transmission and achieve elimination. Mass drug administration (MDA) of artemisinin-based combination therapy (ACT) is capable of reducing malaria transmission where coverage of control interventions is already high, though the impact is short-lived. Combining ACT with ivermectin, an oral endectocide shown to reduce vector survival, may increase its impact, while also treating ivermectin-sensitive co-endemic diseases and minimising the potential impact of ACT resistance in this context.Methods and analysisMATAMAL is a cluster-randomised placebo-controlled trial. The trial is being conducted in 24 clusters on the Bijagós Archipelago, Guinea-Bissau, where the peak prevalence ofPlasmodium falciparum(Pf) parasitaemia is approximately 15%. Clusters have been randomly allocated to receive MDA with dihydroartemisinin–piperaquine and either ivermectin or placebo. The primary objective is to determine whether the addition of ivermectin MDA is more effective than dihydroartemisinin–piperaquine MDA alone in reducing the prevalence ofP. falciparumparasitaemia, measured during peak transmission season after 2 years of seasonal MDA. Secondary objectives include assessing prevalence after 1 year of MDA; malaria incidence monitored through active and passive surveillance; age-adjusted prevalence of serological markers indicating exposure toP. falciparumand anopheline mosquitoes; vector parous rates, species composition, population density and sporozoite rates; prevalence of vector pyrethroid resistance; prevalence of artemisinin resistance inP. falciparumusing genomic markers; ivermectin’s impact on co-endemic diseases; coverage estimates; and the safety of combined MDA.Ethics and disseminationThe trial has been approved by the London School of Hygiene and Tropical Medicine’s Ethics Committee (UK) (19156) and the Comite Nacional de Eticas de Saude (Guinea-Bissau) (084/CNES/INASA/2020). Results will be disseminated in peer-reviewed publications and in discussion with the Bissau-Guinean Ministry of Public Health and participating communities.Trial registration numberNCT04844905.

show abstract